EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Denosumab and Calcium Homeostasis in Hypercalcaemia of Malignancy and Primary Hyperparathyroidism

Fengye Zhou iD, Ying Liu iD, Chunfang Liang iD, Sufang Yun iD

International Journal of Endocrinology · 2026-01 · 2026 (1)

DOI: 10.1155/ije/6930716 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Endocrinology, online erschienen am 10.11.2026. Verfasst von Fengye Zhou und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy The Affiliated Hospital of Inner Mongolia Medical University Hohhot 010059 Inner Mongolia China nmgfy.com. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Inner Mongolia, Inner Mongolia Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To evaluate short‐term changes in serum calcium and the occurrence of values below prespecified thresholds after denosumab treatment in institutional oncology and primary hyperparathyroidism (PHPT) cohorts, and to interpret these findings within the context of FAERS reporting patterns and published PHPT evidence.

Methods

We retrospectively analysed denosumab‐treated patients at the Affiliated Hospital of Inner Mongolia Medical University; the retrospective study was performed in the Department of Clinical Pharmacy (oncology cohort, 2024; PHPT cohort, 2022–April 2025). Total serum calcium was evaluated at baseline and around Days 3 and 7. A downstream FAERS reanalysis used the fixed 2014Q1–2023Q2 dataset, and published PHPT reports were re‐extracted for actual follow‐up and complications.

Results

In the oncology subgroup with baseline calcium > 2.55 mmol/L, mean paired calcium changed from 3.101 to 2.278 mmol/L at Day 3 ( n = 12; p = 0.0002) and from 3.158 to 1.990 mmol/L at Day 7 ( n = 11; p < 0.0001). In PHPT, the corresponding changes were 3.376 to 2.661 mmol/L at Day 3 ( n = 9; p = 0.0038) and 3.351 to 2.289 mmol/L at Day 7 ( n = 8; p = 0.0013). During Days 1–10, calcium < 2.10 mmol/L occurred in 57/102 oncology patients with non‐low baseline calcium and 4/9 PHPT patients; values < 1.60 mmol/L occurred in 3/102 and 0/9, respectively. Among 1433 FAERS hypocalcaemia reports, 1186 (82.76%) had at least one serious‐outcome code, most often hospitalisation/prolonged hospitalisation (769; 53.66%) or another medically important condition (725; 50.59%). Crude hypocalcaemia reporting proportions were higher for 120 mg than 60 mg, for male than female reports, and for tumour‐related than osteoporosis indications; the youngest evaluable age strata also had higher proportions, but denominators were small, and the comparisons were unadjusted.

Conclusion

In the analysed cohorts, denosumab was followed by short‐term calcium reduction in patients with baseline hypercalcaemia and in the small PHPT cohort. Values below 2.10 mmol/L were common in early follow‐up, whereas values below 1.60 mmol/L were uncommon, and clinical hypocalcaemia was not systematically adjudicated. FAERS hypocalcaemia reports often carried serious‐outcome codes, mainly hospitalisation and other medically important conditions, without establishing incidence, causality or independent risk factors.

Schlagwörter

Stichwörter der Autor:innen

adverse effectdenosumabhypercalcaemiamalignancyoff-label useprimary hyperparathyroidism

Autor:innen und Institutionen

  • Department of Pharmacy The Affiliated Hospital of Inner Mongolia Medical University Hohhot 010059 Inner Mongolia China nmgfy.com.
  • Graduate School Inner Mongolia Medical University Hohhot 010059 Inner Mongolia China immu.edu.cn.
  • Department of Endocrinology The Affiliated Hospital of Inner Mongolia Medical University Hohhot 010059 Inner Mongolia China nmgfy.com.

ORCID-Profile: Fengye Zhou, Ying Liu, Chunfang Liang, Sufang Yun

Förderung

  • Natural Science Foundation of Inner Mongolia
  • Inner Mongolia Medical University

Zitieren

APA

Zhou, F., Liu, Y., Liang, C., & Yun, S. (2026). Denosumab and Calcium Homeostasis in Hypercalcaemia of Malignancy and Primary Hyperparathyroidism. International Journal of Endocrinology, 2026(1). https://doi.org/10.1155/ije/6930716

Vancouver

Zhou F, Liu Y, Liang C, Yun S. Denosumab and Calcium Homeostasis in Hypercalcaemia of Malignancy and Primary Hyperparathyroidism. International Journal of Endocrinology. 2026;2026(1). doi:10.1155/ije/6930716

BibTeX
@article{Zhou2026,
  author = {Zhou, Fengye and Liu, Ying and Liang, Chunfang and Yun, Sufang},
  title = {Denosumab and Calcium Homeostasis in Hypercalcaemia of Malignancy and Primary Hyperparathyroidism},
  journal = {International Journal of Endocrinology},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/ije/6930716}
}
Kostenlos starten →